Copyright
©The Author(s) 2024.
World J Gastroenterol. Apr 7, 2024; 30(13): 1871-1886
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1871
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1871
Table 1 Patient characteristics at baseline
| Characteristic | n = 101 |
| Age, years, median (IQR) | 35 (28.0, 47.0) |
| Sex | |
| Male, n (%) | 60 (59.4) |
| Female, n (%) | 41 (40.6) |
| Duration of UC, years, median (IQR) | 4.8 (1.5, 10.0) |
| Disease extent, n (%) | |
| Left-sided colitis | 18 (17.8) |
| Pancolitis | 83 (82.2) |
| Family history of IBD, n (%) | 7 (6.9) |
| Smoking classification, n (%) | |
| Never smoked | 66 (65.3) |
| Current smoker | 14 (13.9) |
| Ex-smoker | 21 (20.8) |
| Comorbidities, n (%) | |
| Hypertension | 7 (6.9) |
| Dyslipidemia | 6 (5.9) |
| Diabetes mellitus | 3 (3.0) |
| Thrombosis | 2 (2.0) |
| Past history of herpes zoster, n (%) | 1 (1.0) |
| Total Mayo score (n = 54), median (IQR) | 9.0 (7.0,10.0) |
| Partial Mayo score, median (IQR) | 6.0 (4.0, 7.0) |
| Mayo endoscopic subscore (n = 54), median (IQR) | 2.0 (2.0, 3.0) |
| 1, n (%) | 3.0 (5.0, 6.0) |
| 2, n (%) | 26 (48.1) |
| 3, n (%) | 25 (46.3) |
| Intractability, n (%) | |
| Steroid dependent | 48 (47.5) |
| Steroid refractory | 51 (50.5) |
| C-reactive protein (mg/dL), median (IQR) | 0.3 (0.1, 1.0) |
| Albumin (g/dL), median (IQR) | 3.9 (3.5, 4.2) |
| White blood cells (/μL), median (IQR) | 7180.0 (5490.0, 9160.0) |
| Lymphocytes (/μL), median (IQR) | 1506.0 (1083.0, 1874.0) |
| Hemoglobin (g/dL), median (IQR) | 12.3 (11.1, 13.8) |
| Total Cholesterol (mg/dL) (n = 71), median (IQR) | 179.0 (163.0, 199.0) |
| Concomitant drugs at baseline, n (%) | |
| 5-aminosalicylic acid | 68 (67.3) |
| Systemic corticosteroid | 23 (22.8) |
| Topical corticosteroid | 22 (21.8) |
| History of treatment at baseline | |
| Previous corticosteroid, n (%) | 99 (98.0) |
| Previous immunomodulator, n (%) | 70 (69.3) |
| Previous cytapheresis, n (%) | 27 (26.7) |
| Previous tacrolimus, n (%) | 31 (30.7) |
| Previous biologics, n (%) | 67 (66.3) |
| Anti-TNF-α agent, n (%) | 63 (62.4) |
| Infliximab | 38 (37.6) |
| Adalimumab | 27 (26.7) |
| Golimumab | 19 (18.8) |
| Number of anti-TNF-α agent failure, n (%) | |
| 1 agent | 44 (43.6) |
| 2 agents | 17 (16.8) |
| 3 agents | 2 (2.0) |
| Vedolizumab, n (%) | 11 (10.9) |
| Anti-TNF-α agent and vedolizumab, n (%) | 7 (6.9) |
- Citation: Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World J Gastroenterol 2024; 30(13): 1871-1886
- URL: https://www.wjgnet.com/1007-9327/full/v30/i13/1871.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i13.1871